Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors by Christian U. Blank, Deborah J. Wong, Thai H. Ho, Todd M. Bauer, Carrie B. Lee, Fabiola Bene-Tchaleu, Jing Zhu, Xiaosong Zhang, Edward Cha, Mario Sznol

Get full text

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study by Jessica C Hassel, Mark R Middleton, Alexander N Shoushtari, Omid Hamid, Paolo A Ascierto, Todd M Bauer, John M Kirkwood, Friedegund Meier, Marlana Orloff, Paul C Lorigan, Chris Holland, Cornelia Mauch, Ramakrishna Edukulla, April K S Salama, Thomas R Jeffry Evans, Shaad E Abedin

Get full text

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study by Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y. C. Heng, Jennifer Knox, Martin H. Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers

Get full text

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study by Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers

Get full text

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors by Thomas Yau, Ignacio Garrido-Laguna, Pierre-Eric Juif, Markus Joerger, Anna Spreafico, Todd M Bauer, Chia-Chi Lin, Armando Santoro, Richard Greil, Helen Evans, Marc Pelletier, Toshikiko Doi, Maria-Elisabeth Goebeler, Viviana Cremasco, Marie Luise Hütter-Krönke, Antonella Perotti, Darlene Lu, Louise Barys, Claire Fabre

Get full text

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study by Rui Wang, Antoine Italiano, Shubham Pant, Johann De Bono, Todd M Bauer, Christophe Massard, Chia-Chi Lin, Roberto Iacovelli, Martin Gutierrez, Mansoor Saleh, Helen Lee, Gennaro Daniele, Paolo Andrea Zucali, Marielle Chiron, Bradley C Carthon, Robin Meng, Giovanni Abbadessa, Marcello Tucci, Wu-Chou Su, Alastair Greystoke, Ying-Chun Shen, Matteo Perrino, Yingwen Dong, Laure Loumagne, Lucie Lépine

Get full text

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) by Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore

Get full text